Tarun Saluja | Director, Clinical Development
International Vaccine Institute

Day 2 - Wednesday 1st April @ 17:25

Panel: Human Challenge Models: A New Gold Standard?

li>
•     Evaluate HCMs as faster, cost-effective alternatives to Phase III trials, especially for outbreak-prone diseases.
•     Share real-world examples from CEPI’s CHIM consortium and other global initiatives.
•     Discuss regulatory and ethical frameworks for participant safety and trial approval.
•     Explore operational challenges including infrastructure, biosafety, and assay standardization.
•     Examine the role of immunobridging in translating animal data to human efficacy.
•     Debate future potential of HCMs in mainstream vaccine licensure, including AI and biomarker integration.

Tarun Saluja, Director, Clinical Development, International Vaccine Institute

Daniel Fullen, Research and Development Innovations Lead, CEPI

Bassam Hallis, Deputy Director, Head of Vaccine Development & Evaluation Centre, UK Health Security Agency

×

Bassam Hallis / Panel: Human Challenge Models: A New Gold Standard?

Bassam Hallis, Deputy Director, Head of Vaccine Development & Evaluation Centre,
UK Health Security Agency

Dr Bassam Hallis OBE is the Deputy Director and the lead for the Vaccine Development and Evaluation Centre.Bassam has over 35 years’ experience working with public sector, industry and academia in the development and evaluation of vaccines and therapeutics. He provides scientific and operational...

CloseMore

Day 3 - Thursday 2nd April @ 09:10

Panel: Designing Clinical Trials for Emerging Threats